Keyphrases
Chronic Lymphocytic Leukemia
100%
Acute Myeloid Leukemia
84%
Natural Killer Cells
66%
T Cells
47%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
44%
Tumor
39%
Leukemia
36%
Graft-versus-host Disease (GvHD)
30%
Overall Survival
29%
B Cells
29%
Ibrutinib
28%
Macrophages
27%
Relapsed or Refractory
23%
Acute Lymphoblastic Leukemia
22%
Leukemia Patients
21%
Rituximab
20%
In Cancer
20%
MicroRNA
19%
Multiple Myeloma
19%
Clinical Trials
19%
Monocytes
18%
Mantle Cell Lymphoma
18%
Gene Expression
17%
Chronic Myeloid Leukemia
17%
Chemotherapy
17%
Complete Remission
17%
Interleukin-1β
16%
High Risk
16%
Confidence Interval
16%
Progression-free Survival
16%
Mycobacterium Tuberculosis (M. tb)
16%
Polystyrene
15%
Immune Response
15%
Tumor Cells
15%
Interferon-α (IFN-α)
15%
Hematological Malignancies
14%
Fc Receptor
14%
Hematopoietic Cell Transplantation
14%
Lymphoma
14%
Non-Hodgkin Lymphoma
14%
Experimental Autoimmune Encephalomyelitis
13%
Chronic Lymphocytic Leukemia Cells
13%
Lung
13%
Interleukin-2
13%
CD8+ T Cells
13%
Bone Marrow
13%
Inflammation
13%
Myelodysplastic Syndrome
12%
Diffuse Large B-cell Lymphoma (DLBCL)
12%
Monoclonal Antibody
12%
DNA Methylation (DNAm)
12%
Transplantation
12%
Apoptosis
12%
Relapsed or Refractory Acute Myeloid Leukemia
12%
Follicular Lymphoma
12%
Fludarabine
12%
Breast Cancer
12%
Lenalidomide
12%
Phase II Study
12%
Epstein-Barr Virus
12%
Children's Oncology Group
11%
Phase II Trial
11%
Dendritic Cells
11%
Methylation
11%
Complete Response
11%
Unsaturated Polyester Resin
11%
Liver
11%
Targeted Therapy
11%
Cyclophosphamide
10%
Chimeric Antigen Receptor T Cells (CAR-T)
10%
Overexpression
10%
Resin
10%
Granulocyte Colony-stimulating Factor (G-CSF)
10%
Toll-like
10%
Transcription Factor
10%
Malignancy
10%
Clinical Outcomes
10%
Innate Immune Response
10%
Cytotoxicity
10%
Nanoparticles
10%
Peripheral Blood
9%
Carbon Nanofibers
9%
Cancer Cells
9%
Hematopoietic Stem Cells
9%
Newly Diagnosed
9%
Mouse Model
9%
Disease Progression
9%
Acute Leukemia
9%
Interleukin-12 (IL-12)
9%
Interleukin-15 (IL-15)
9%
Human Monocytes
9%
Adverse Events
9%
Older Patients
9%
Phase I Study
9%
Lipopolysaccharide
9%
Lymphocytes
9%
Event-free Survival
8%
Hazard Ratio
8%
Quantitative PCR
8%
Lymphoma Patients
8%
Medicine and Dentistry
Acute Myeloid Leukemia
63%
B-Cell Chronic Lymphocytic Leukemia
62%
Neoplasm
56%
Malignant Neoplasm
51%
Disease
47%
T Cell
32%
Hematopoietic Cell
31%
Overall Survival
29%
B Cell
29%
Leukemia
28%
Ibrutinib
26%
Transplantation
23%
Cell Transplantation
22%
Natural Killer Cell
21%
Acute Lymphoblastic Leukemia
20%
Chemotherapy
20%
Oncology
20%
Clinical Trial
16%
Non-Hodgkin Lymphoma
16%
In Vitro
16%
Multiple Myeloma
15%
Breast Cancer
15%
Progression Free Survival
15%
Cancer
15%
Mantle Cell Lymphoma
14%
Infection
13%
Diffuse Large B-Cell Lymphoma
13%
microRNA
12%
Myelodysplastic Syndrome
12%
Immunotherapy
12%
Rituximab
12%
Adverse Event
11%
Graft Versus Host Reaction
11%
Programmed Cell Death
11%
Chronic Myelogenous Leukemia
10%
Immunity
10%
Pediatrics
10%
Diagnosis
10%
Targeted Therapy
9%
B-Cell Lymphoma
9%
Hematologic Malignancy
9%
Cell Therapy
9%
Follicular Lymphoma
9%
Colorectal Carcinoma
9%
Surgery
9%
Messenger RNA
9%
Leukemia Cell
8%
Hematopoietic Stem Cell Transplantation
8%
Receptor
8%
Epstein Barr Virus
8%
Acute Leukemia
8%
Tumor Cell
8%
Gene Expression
8%
Cytotoxicity
8%
Macrophage
8%
Biopsy Technique
8%
Lung
8%
Lymphocyte
8%
Cancer Cell
8%
Bruton Tyrosine Kinase
7%
Karyotype
7%
Melanoma
7%
Bruton Tyrosine Kinase Inhibitor
7%
Cytotoxic T-Cell
7%
Hodgkin's Lymphoma
7%
Immune Response
7%
Event Free Survival
7%
Methylation
6%
Lymphocytic Lymphoma
6%
Morphology
6%
Minimal Residual Disease
6%
Drug Megadose
6%
Cyclophosphamide
6%
Lenalidomide
6%
Biological Marker
6%
Immunohistochemistry
6%
Allograft
6%
Cell Line
6%
Stem Cell
6%
Hazard Ratio
6%
Arm
6%
Ex Vivo
6%
Monoclonal Antibody
6%
Prognostic Factor
6%
Stem Cell Transplant
6%
Signal Transduction
6%
Venetoclax
6%
Cytarabine
6%
Cytokine
6%
Metastatic Carcinoma
6%
Human Immunodeficiency Virus
5%
Immunosuppressive Treatment
5%
Survival Rate
5%
Allogeneic Hematopoietic Stem Cell Transplantation
5%
Fluorescence in Situ Hybridization
5%
Recurrent Disease
5%
Lymphoproliferative Disease
5%
Acute Graft Versus Host Disease
5%
B Lymphocyte Receptor
5%
Chimeric Antigen Receptor T-Cell Immunotherapy
5%